Comparison between recombinant virus assay and live virus assay on evaluating anti-HIV-1 drugs.
- Author:
Hui-hui CHONG
1
;
Si-hong XU
;
Jing-yun LI
;
You-chun WANG
Author Information
- Publication Type:Journal Article
- MeSH: Anti-HIV Agents; pharmacology; Drug Evaluation; HIV-1; drug effects; Recombination, Genetic
- From: Chinese Journal of Experimental and Clinical Virology 2011;25(1):73-75
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compaire results of recombinant virus assay and live virus assay on evaluateing anti-HIV-1 drugs.
METHODSThe pseudoviruse was generated by cotransfection of the plasmid B01 containing gp160 genes and pSG3 delta env plasmid. After co-incubation of pseudovirus with serially diluted drug, the EC50 and ED50 were calculated according to RLU(relative light unit) for each drug. After co-incubation of live virus with serially diluted drug, the EC50 was calculated according to cytopathic effect.
RESULTSEC50 of IDV measured by the recombinant virus assay and live virus assay was 88.9 nmol/L, 89.5 nmol/L, respectively, while EC50 of NVP measured by the recombinant virus assay and live virus assay was 0.36 micromol/L, 0.23 micromol/L, respectively. The recombinant virus assay showed good reproducibility with coefficient variation of 0, however coefficient variation of live virus assay reached to 60%. ED50 of IDV and NVP measured by the recombinant virus assay were 70.6 nmol/L and 0.62 micromol/L, respectively. Coefficient variations for IDV and NVP were 14.3% and 9.7%, respectively.
CONCLUSIONThe pseudoviruses could be used in evaluating anti-HIV-1 drugs. The recombinant virus assay showed good reproducibility and could calculate not only the EC50 but also the ED50 of drugs.
